News

Hillhurst gets $6.3M funding for HBI-002 clinical study

Hillhurst Biopharmaceuticals said it’s been awarded $6.3 million to fund a Phase 2a clinical study to test the efficacy of HBI-002, its low-dose liquid formulation of carbon monoxide, in preserving dopaminergic neurons, those that are lost to Parkinson’s disease, with the goal of slowing or stopping disease progression. The…

ANPD001 eases motor symptoms, early trial data show

The first three patients treated with ANPD001, a cell therapy for Parkinson’s disease, showed reduced motor symptoms and improved daily functioning over six months, without any serious side effects. That’s according to early data from the Phase 1/2a ASPIRO (NCT06344026) study, an open-label clinical trial testing the…

Students aim to boost diversity in Parkinson’s exercise providers

Two University of Michigan-Flint doctorate students received a $50,000 grant to support diversity among exercise providers offering care to people with Parkinson’s disease. The grant, from The Michigan Health Equity Challenge, will help the pair’s Move to Represent initiative train 10 physical and occupational therapists of color to…

Processed food tied to higher risk of early Parkinson’s symptoms

People who eat large amounts of highly processed foods are more likely to develop early Parkinson’s disease symptoms, a study found. “There’s growing evidence that diet might influence the development of Parkinson’s disease,” Xiang Gao, MD, PhD, co-author of the study and a professor at Fudan University in China, said…

MJFF expands training program for movement disorder specialists

The Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program, which trains specialists in improving access to Parkinson’s disease care. The program provides funding each year for medical centers to train physicians to become Parkinson’s specialists.

RNA-editing enzyme may be novel treatment target in Parkinson’s

The dysregulation of RNA editing within astrocytes (neuron-supporting cells) seems to induce chronic inflammation and ultimately contributes to the loss of nerve cells in people with Parkinson’s disease, according to a recent study. This dysregulation is triggered by alpha-synuclein clumping, which is a characteristic feature of Parkinson’s. RNA editing…